Literature DB >> 15322802

[Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease].

T Dintelmann1, J Sold, F Grehn.   

Abstract

OBJECTIVE: Upper lid retraction associated with thyroid eye disease may result in conjunctival and corneal exposure as well as in an esthetic problem. We evaluated the effect of botulinum toxin injections in order to lower the upper lid.
METHODS: This prospective study included 19 eyes of 13 female patients presenting with scleral exposure aged 28-50 years. We injected 5-15 IE botulinum toxin A (Botox) transconjunctivally into the levator muscle. Lid position, negative side effects, and patient satisfaction were evaluated.
RESULTS: Lid retraction improved from 2.4 mm (+/-1.4 mm) prior to injection to 0.5 mm (+/-2.3 mm) 4 weeks after injection. In 11 of 19 eyes 4 weeks after injection and in 8 of 14 eyes 12 weeks after injection scleral exposure had resolved. Diplopia did not occur and tear production was not influenced. Two eyes had transient ptosis. Lid lag increased from 0.34 (+/-0.6 mm) to 0.84 mm (+/-0.9 mm). Of 13 patients, 8 were satisfied with the result.
CONCLUSION: Botulinum toxin A injection provides effective treatment especially in mild lid retraction and as a temporary solution for patients with unstable thyroid disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15322802     DOI: 10.1007/s00347-004-1091-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  10 in total

1.  Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction--a pilot study.

Authors:  F Träisk; L Tallstedt
Journal:  Acta Ophthalmol Scand       Date:  2001-12

2.  Chemodenervation in treatment of upper eyelid retraction.

Authors:  S B Ozkan; D Can; M F Söylev; A K Arsan; S Duman
Journal:  Ophthalmologica       Date:  1997       Impact factor: 3.250

3.  Clostridium botulinum toxins: nature and preparation for clinical use.

Authors:  J Melling; P Hambleton; C C Shone
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

4.  Botulinum toxin A induced protective ptosis.

Authors:  G G Adams; C M Kirkness; J P Lee
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

5.  Control of eyelid retraction associated with Graves' disease with botulinum A toxin.

Authors:  A W Biglan
Journal:  Ophthalmic Surg       Date:  1994-03

6.  Persisting hypotropias following protective ptosis induced by botulinum neurotoxin.

Authors:  P L Heyworth; J P Lee
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

7.  Pharmacologic weakening of extraocular muscles.

Authors:  A B Scott; A Rosenbaum; C C Collins
Journal:  Invest Ophthalmol       Date:  1973-12

Review 8.  Eyelid surgery in dysthyroid ophthalmopathy.

Authors:  A Hedin
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

9.  Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection.

Authors:  Jimmy M Uddin; Peter D Davies
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

10.  Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy.

Authors:  R Ebner
Journal:  J Clin Neuroophthalmol       Date:  1993-12
  10 in total
  2 in total

1.  Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease.

Authors:  David B Granet; Nickisa Hodgson; Kyle J Godfrey; Ricardo Ventura; Don O Kikkawa; Leah Levi; Michael Kinori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-10       Impact factor: 3.117

Review 2.  [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction].

Authors:  B Wabbels; M Förl
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.